Edition:
United States

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

230.02USD
19 Jun 2018
Change (% chg)

-- (--)
Prev Close
$230.02
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
347,965
52-wk High
$248.20
52-wk Low
$191.53

Latest Key Developments (Source: Significant Developments)

FDA Continues To Recommend Magellan Lead Tests Not Be Used With Samples Taken From Vein
Thursday, 22 Mar 2018 03:26pm EDT 

March 22 (Reuters) - U.S. FDA ::U.S FDA PROVIDES STATEMENT ON FINDINGS FROM ONGOING INVESTIGATION INTO LEAD TESTING ISSUES.U.S. FDA-CONCLUDED THAT STUDIES PERFORMED BY BD WERE ROBUST & SHOWED THERE WAS SIGNIFICANT CHANCE OF FALSE RESULTS WITH MAGELLAN’S LEADCARE TESTS ‍​.U.S FDA SAYS CONTINUES TO RECOMMEND THAT MAGELLAN LEAD TESTS NOT BE USED WITH BLOOD SAMPLES TAKEN FROM THE VEIN.U.S FDA SAYS MAGELLAN’S LEAD TEST SYSTEMS CAN CONTINUE TO BE USED WITH BLOOD SAMPLES FROM A FINGER OR HEEL STICK.AT FDA'S REQUEST, BD IS CONDUCTING TESTING TO DETERMINE IF LAB TESTS OTHER THAN MAGELLAN LEAD TESTS ARE AFFECTED BY THIURAM INTERFERENCE​‍​.  Full Article

Becton, Dickinson To Divest Remaining Investment In Vyaire Medical
Monday, 19 Mar 2018 11:38am EDT 

March 19 (Reuters) - Becton, Dickinson And Co ::BD TO DIVEST REMAINING INVESTMENT IN VYAIRE MEDICAL TO FUNDS MANAGED BY APAX PARTNERS.‍BD WILL RECEIVE $435 MILLION IN CASH​.‍DIVESTITURE WILL NOT HAVE A MATERIAL IMPACT TO BD REVENUE OR ADJUSTED EARNINGS FOR FISCAL 2018​.‍EXPECTS TO RECORD A GAIN ON TRANSACTION AT TIME OF CLOSING​.‍BD INTENDS TO USE PROCEEDS FROM DEAL IN LINE WITH ITS "BROADER CAPITAL ALLOCATION STRATEGY​".  Full Article

Becton Dickinson Files For Offering EUR 300 Mln Add. 0.368% Notes
Friday, 16 Feb 2018 06:36am EST 

Feb 16 (Reuters) - Becton Dickinson And Co ::BECTON DICKINSON AND CO FILES FOR OFFERING EUR 300 MILLION AGGREGATE PRINCIPAL AMOUNT OF ADDITIONAL 0.368% NOTES DUE 2019 - SEC FILING.BECTON DICKINSON AND CO FILES PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED MAY 8, 2017 ‍​.BECTON DICKINSON AND CO SAYS UPON CONSUMMATION OF THE OFFERING, AGGREGATE PRINCIPAL AMOUNT OUTSTANDING OF 0.368% NOTES DUE 2019 WILL BE EUR 1 BILLION.  Full Article

Becton Dickinson Says Received Pre-Market Approval From FDA For BD Onclarity HPV Assay
Tuesday, 13 Feb 2018 06:59am EST 

Feb 13 (Reuters) - Becton Dickinson And Co ::FDA APPROVES NEW HPV TEST THAT DETECTS AND IDENTIFIES HPV GENOTYPES THAT PUT WOMEN AT HIGH RISK FOR CERVICAL CANCER.  Full Article

Becton Dickinson Q1 Loss Per Share $0.76
Tuesday, 6 Feb 2018 06:03am EST 

Feb 6 (Reuters) - Becton Dickinson And Co ::BD ANNOUNCES RESULTS FOR 2018 FIRST FISCAL QUARTER; PROVIDES FISCAL 2018 GUIDANCE UPDATED FOR INCLUSION OF BARD.Q1 LOSS PER SHARE $0.76.Q1 REVENUE $3.08 BILLION.BECTON DICKINSON - EXPECTS FISCAL 2018 ADJUSTED EARNINGS PER SHARE, INCLUDING ACCRETION FROM C.R. BARD ACQUISITION, TO BE BETWEEN $10.85 AND $11.00.BECTON DICKINSON - REAFFIRMS ACQUISITION OF C.R. BARD EXPECTED TO BE ACCRETIVE TO ADJUSTED EARNINGS PER SHARE ON A HIGH-SINGLE DIGIT BASIS IN FISCAL YEAR 2019.BECTON DICKINSON - QTRLY REVENUE INCLUDES ESTIMATED 110 BASIS POINT ADVERSE IMPACT FROM CHANGE IN U.S. DISPENSING BUSINESS MODEL.QTRLY ADJUSTED EARNINGS PER SHARE $2.48.Q1 EARNINGS PER SHARE VIEW $2.41, REVENUE VIEW $3.05 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $10.88 -- THOMSON REUTERS I/B/E/S.2018 ‍REVENUES, INCLUDING ACCRETION FROM C.R. BARD DEAL, ARE EXPECTED TO INCREASE ABOUT 30 PERCENT TO 31 PERCENT ON A REPORTED BASIS​.BECTON DICKINSON - ON COMPARABLE, CURRENCY-NEUTRAL BASIS THAT INCLUDES REVS OF C.R. BARD IN CURRENT, PRIOR YEAR, FY 2018 REVENUE EXPECTED TO GROW 4.5-5.5 PERCENT.FY2018 EARNINGS PER SHARE VIEW $10.88, REVENUE VIEW $15.87 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

BD Statement On FDA Warning Letter For Preanalytical Systems Business Unit
Friday, 12 Jan 2018 09:23am EST 

Jan 12 (Reuters) - Becton Dickinson And Co ::BD STATEMENT ON FDA WARNING LETTER FOR PREANALYTICAL SYSTEMS BUSINESS UNIT.BECTON DICKINSON - AFTER FDA INSPECTION IN JULY, TOOK ACTION THAT CO BELIEVED FULLY ADDRESSED AGENCY'S INSPECTIONAL OBSERVATIONS.BECTON DICKINSON - "CAREFULLY REVIEWING" FDA'S FEEDBACK OUTLINED IN LETTER WITH HIGHEST SENSE OF URGENCY, TO PROVIDE FULL RESPONSE ON OR BEFORE FEB 1.  Full Article

FDA Issues Warning Letter To Becton Dickinson & Co
Thursday, 11 Jan 2018 01:25pm EST 

Jan 11 (Reuters) - U.S. Food and Drug Administration::FDA WARNS BECTON DICKINSON & COMPANY OF SIGNIFICANT VIOLATIONS OF THE LAW AS PART OF ONGOING INVESTIGATION INTO LEAD TESTING ISSUES‍​.U.S. FDA SAYS BECTON DICKINSON'S VIOLATIONS INCLUDE MARKETING MODIFIED VERSIONS OF CERTAIN BD VACUTAINER BLOOD COLLECTION TUBES WITHOUT REQUIRED APPROVAL.FDA SAYS INSPECTION SHOWED BD VIOLATED LAW BY MAKING SIGNIFICANT CHANGE TO SOME OF ITS DEVICES WITHOUT NOTIFYING FDA.‍FDA​ SAYS VIOLATIONS WERE DISCOVERED THROUGH AN INSPECTION OF BECTON DICKINSON ’S NEW JERSEY FACILITY.FDA SAYS BECTON DICKINSON HAS UNTIL FEB 1, 2018 TO NOTIFY FDA ABOUT SPECIFIC STEPS CO HAS TAKEN TO ADDRESS FDA IDENTIFIED VIOLATIONS.FDA - BD DID NOT ADDRESS COMPLAINT OF VARIABILITY IN RESULTS WHEN SOME BD VACUTAINER BLOOD COLLECTION TUBES WERE USED WITH MAGELLAN DIAGNOSTICS’ LEADCARE TEST SYSTEMS.  Full Article

BD Announces Extension Of Exchange Offers And Consent Solicitations For C. R. Bard Inc Notes
Thursday, 28 Dec 2017 06:56am EST 

Dec 28 (Reuters) - Becton Dickinson And Co ::BD ANNOUNCES EXTENSION OF EXCHANGE OFFERS AND CONSENT SOLICITATIONS FOR C. R. BARD, INC. NOTES.BECTON DICKINSON - EXTENDING EXPIRATION DATE OF EXCHANGE OFFERS AND CONSENT SOLICITATIONS TO 5:00 P.M., NEW YORK CITY TIME, DEC 28, 2017.  Full Article

BD board increases dividend
Monday, 20 Nov 2017 04:30pm EST 

Nov 20 (Reuters) - Becton Dickinson And Co ::BD board increases dividend.Becton Dickinson And Co - ‍declared a quarterly dividend of $0.75 per common share, an increase of 2.7 percent from previous quarter​.  Full Article

Merit Medical signs purchase agreement with BD for divestment assets
Thursday, 16 Nov 2017 06:30am EST 

Nov 16 (Reuters) - Merit Medical Systems Inc ::Merit Medical signs purchase agreement with BD for divestment assets.Merit Medical Systems Inc - ‍purchase price for product lines and related assets to be acquired is $100 million​.Merit Medical Systems Inc - ‍purchase price for product lines and related assets to be acquired is $100 million​.Merit Medical Systems- ‍intends to finance acquisition at closing through borrowings which are currently available under its revolving credit facility​.Merit Medical Systems Inc - ‍transaction is also expected to expand operating margins and increase cash flow​.Merit - ‍has signed asset purchase agreement with bd to acquire certain assets which bd proposes to sell in connection with acquisition of C.R. Bard​.Merit Medical Systems Inc - ‍transaction is expected to be accretive to both GAAP and non-GAAP earnings in 2018 for Merit's shareholders​.Merit Medical Systems Inc - ‍expects acquisition to provide $0.10-$0.19 in adjusted non-GAAP earnings per share accretion in fiscal year 2018​.Merit Medical Systems Inc - ‍ expects deal to be accretive by 50-120 basis points to co's adjusted gross margins over a period of six to twelve months​.  Full Article

Photo

U.S. investigates bloodstream infections for link to heparin syringes

SHANGHAI/CHICAGO Health agencies are investigating an outbreak of bloodstream infections in children from four U.S. states that may be linked to heparin and saline syringes made by Becton Dickinson and Co, the agencies told Reuters. The U.S. Centers for Disease Control and Prevention has confirmed 14 cases of bloodstream infections in children caused by the same strain of the Serratia marcescens bacterium, the agency's lead investigator on the outbreak said in a telephone interview.